OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI ...
Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
OpenAI CEO Sam Altman will brief U.S. officials on super-agents—AI systems set to revolutionize software development, finance ...
Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in ...
"And of course it's smarter than us. Of course, it can do things we can't, but also who really cares? I think it's only weird ...
Stargate is little more than an extension of Sam Altman's powerful AI company, anonymous sources told the Financial Times.
OpenAI CEO Sam Altman has made several predictions about where we're headed on AGI, superintelligence, agentic AI — and when we might get there.
Retro Biosciences is raising $1 billion, with the ultimate goal of using its customized AI to extend human lifespan by 10 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback